HCV guidance
This article was originally published in The Gray Sheet
Executive Summary
Comments are due to the agency by Jan. 6, 2000 on recently released draft guidance on premarket approval applications for assays for diagnosis or monitoring of hepatitis C that would allow use of unapproved HCV-RNA assays as corroborating evidence, as long as supporting information is provided
You may also be interested in...
Abbott AxSYM HCV Test Needs Confirmation; Panel Recommends Approval
Positive test results with Abbott's AxSYM hepatitis C virus (HCV) microparticle enzyme immunoassay (MEIA) should be verified with a specific or supplemental test before being reported to the patient, FDA's Microbiology Devices Panel recommended at its Jan. 21 meeting in Rockville, Maryland.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.